Michele B. Kaufman, PharmD, BSc, RPh, is a freelance medical writer based in New York City, a clinical pharmacist at New York Downtown Hospital, and adjunct faculty at Touro College of Pharmacy.
References
- Bratulic A. Celgene’s psoriasis drug apremilast meets primary endpoint in Phase III study. Published March 3, 2013. Available at www.firstwordpharma.com/forward/emailref?path=node/1061980. Accessed March 4, 2013.
- Lilly discontinues Phase 3 rheumatoid arthritis program for tabalumab based on efficacy results. Published February 7, 2013. Available at https://investor.lilly.com/releasedetail.cfm?ReleaseID=738769. Accessed February 7, 2013.
- CDC Grand Rounds. Prescription Drug Overdoses—a U.S. Epidemic. Published January 13, 2013. Available at www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm. Accessed February 5, 2013.
- Substance Abuse and Mental Health Services Administration. The scope of substance abuse in America. Published October 2012. Available at www.samhsa.gov/prevention/nationalpreventionmonth. Accessed February 4, 2013.
- Epidemic: Responding to America’s prescription drug abuse crisis. Published April 2011. Available at www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf. Accessed February 5, 2013.
- Alliance of States with Prescription Monitoring Programs. About the alliance. Available at www.pmpalliance.org/content/about-alliance. Accessed February 4, 2013.
- New York State Department of Health. Frequently asked questions part C chapter 447 laws of 2012 (Controlled Substance Schedule Changes. Published November 2012. Available at www.health.ny.gov/professionals/narcotic/laws_and_regulations/part_c-chapter_447-laws_of_2012-faq.htm. Accessed February 4, 2013.
- Liscinsky M. FDA issues draft guidance on abuse-deterrent opioids. Published January 9, 2013. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm. Accessed February 4, 2013.
- Galloway JB, Mercer L, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72:229-234.
- Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-895.
- Geber J. Fatal reactions prompt Omontys recall. Published February 24, 2013. Available at www.medpagetoday.com/HematologyOncology/Anemia/37509. Accessed February 24, 2013.
